Actavis buys UK generics firm for £306m
This article was originally published in Scrip
Executive Summary
Actavis, which will shortly close its $66bn acquisition of Allergan, has agreed to buy privately held UK-focused generics firm Auden Mckenzie for around £306m in cash, plus a two-year royalty on one of Auden Mckenzie's products. The deal promises to make Actavis the number one supplier of generic pharmaceuticals in the UK.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.